Basic Information
| LncRNA/CircRNA Name | circLDLRAD3 |
| Synonyms | |
| Region | |
| Ensemble | |
| Refseq |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | pancreatic cancer |
| ICD-0-3 | C25 |
| Methods | qPCR |
| Sample | pancreatic cancer and their paired adjacent pancreatic tissues, blood, The normal pancreatic cell lines, HPC-Y5 and HPDE6-C7, The pancreatic cancer cell lines, Capan-2, Panc-1, SW1990, and AsPC-1 |
| Expression Pattern | up-regulated |
| Function Description | Circ-LDLRAD3 was up-regulated in pancreatic cancer cell lines (P < 0.01), pancreatic cancer tissues (P < 0.01), and plasma samples from patients with pancreatic cancer (P < 0.01). High expression of circLDLRAD3 was significantly associated with venous invasion, lymphatic invasion, and metastasis. The area under the ROC curve of circ-LDLRAD3 alone or combination with CA19-9 was 0.67 and 0.87, respectively, with a sensitivity and specificity of 0.5738 (alone) and 0.7049 (alone), and 0.8033 (combination) and 0.9355 (combination), respectively. |
| Pubmed ID | 29307994 |
| Year | 2017 |
| Title | Circular RNA circ-LDLRAD3 as a biomarker in diagnosis of pancreatic cancer |
External Links
| Links for circLDLRAD3 | GenBank HGNC NONCODE |
| Links for pancreatic cancer | OMIM COSMIC |